KENNEWICK, Wash.--(BUSINESS WIRE)--Advanced Medical Isotope Corporation ("AMIC") (OTC: ADMD), a late stage development company engaged in the development of brachytherapy devices for therapeutic applications, today announced the retention of world-class Investor Relations firm Circadian Group, an online-focused leader in shareholder development and engagement, with a proven track record in the medical device, pharmaceutical and biotech industries.
"2016 is going to be a pivotal year for AMIC" - Circadian will focus on broadcasting the Company’s past success, current corporate profile and future catalysts to a broad spectrum of new potential Investors worldwide. As an industry leader, Circadian uses the most modern techniques in procuring interest in exciting and rapidly-growing companies such as AMIC from a broad range of Investors; readers are encouraged to reach out to either of the contacts below with any questions.
Tyler M. Troup, B.Comm, Managing Director of Circadian stated:
“AMIC fits our firm’s mission statement to a tee – working with small cap companies in the latter stages of early growth which are working toward a near-term transformational catalyst-- as the firm works towards potential approval from the FDA on their 3 revolutionary products.
“Some of the best ideas and businesses are ones who re-engineer a “better mousetrap,” and AMIC far exceeds simple betterment of brachytherapy and therapeutic isotopes delivery devices. Y-90 appears to have a relatively superior efficacious therapeutic index while limiting collateral damage which is optimized by AMIC’s patented delivery techniques and method of action. In simpler terms, the suite of Y-90 products appear to be more effective and safer than competing products which, in our opinion, is how you disrupt and capture an entire industry.
“We are very optimistic for the future of AMIC in not only their business prospects but also in the quest to help cancer patients live a longer, less painful life.”
James C. Katzaroff, AMIC Founder, Chairman and CEO stated, “Circadian Group is an excellent fit for AMIC. Circadian’s expertise in our industry at our stage of development, along with outstanding recommendations from current and past clients contributed to our decision to retain them. We believe that 2016 is going to be a pivotal year for AMIC, and we feel confident that Circadian is a strong and proven partner to help us educate the public on what we have accomplished and where we plan to take the Company in the future.”
About Circadian Group
Circadian Group is an Ontario, Canada and Sarasota, Florida based Investor Relations and media creation/ distribution firm primarily focused on the healthcare and technology sectors.
As a true pioneer in their field, the firm uses a comprehensive and integrated suite of online “pull” strategies to showcase a client’s value proposition and future prospects in an engaging format-- this is in contrast to the traditional sense of the term “IR” where Investor interest is anticipated versus cultivated.
Circadian prides itself on working with select small cap companies in the latter stages of early growth which are working toward a near-term transformational catalyst to bolster an already distinguished track record of uncovering successful companies before Wall Street and the mainstream media.
About Advanced Medical Isotope Corporation
Advanced Medical Isotope Corporation (ADMD) is a late stage development company engaged in the development of brachytherapy devices for therapeutic applications. AMIC's focus is on transitioning to full operations upon receipt of FDA clearance for its patented brachytherapy cancer products. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. The Company intends to outsource material aspects of manufacturing, distribution, sales and marketing for its products in the United States and to enter into licensing arrangements outside of the United States, though the Company will evaluate its alternatives before finalizing its plans. For more information, please visit our website, www.isotopeworld.com.
Safe Harbor Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, AMIC's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.
Advanced Medical Isotope Corporation
James C. Katzaroff, CEO
Circadian Group, Investor Relations
+1 (866) 950-8300